Lipoprotein retention and inflammation due to regurgitant blood flow as

part of the natural history of degenerative ascending aortic aneurysms

David Freiholtz^{1,2} MD, Karin Lång² MSc, Otto Bergman² PhD, Christian Olsson¹ MD PhD,

1

Malin Granbom Koski¹ MD, Michael Dismorr¹ MD PhD, Cecilia Österholm³ PhD, Kenneth

Caidahl MD PhD⁴, Anders Franco-Cereceda¹ MD PhD, Per Eriksson² PhD, Anton Gisterå²

MD PhD. Hanna M Biörck²* PhD

¹Section of Cardiothoracic Surgery, Department of Molecular Medicine and Surgery,

Karolinska Institutet, Stockholm, Sweden

²Division of Cardiovascular Medicine, Center for Molecular Medicine, Karolinska

University Hospital, Solna, Department of Medicine, Karolinska Institutet, Stockholm,

Sweden

³Clinical Genetics, Department of Molecular Medicine and Surgery, Karolinska Institutet,

Stockholm, Sweden

⁴Clinical Physiology, Department of Molecular Medicine and Surgery, Karolinska Institutet,

Stockholm, Sweden

*Address of correspondence

Dr. Hanna M. Björck

NKS Bioclinicum J8:20, Visionsgatan 4

SE-171 64 Stockholm, Sweden

Phone +46 72 2144491

hanna.bjorck@ki.se

ORCID ID: https://orcid.org/0000-0002-9155-3609

Word count: 3029

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Manuscript type: Original research

Abstract

BACKGROUND: An abnormal accumulation of immune cells and a disrupted lipoprotein

metabolism has previously been described as part of the pathogenesis of ascending aortic

aneurysm in patients with tricuspid aortic valves. The factor driving the accumulation of

immune cells remains unclear; however, it may be considered in light of the observation that

proximal aortic dilatation often occurs alongside aortic regurgitation but rarely with aortic

stenosis. In the present study we aim to investigate the natural history of ascending aortic

aneurysm in patients with tricuspid aortic valves by assessing the association between aortic

regurgitation and vascular deterioration.

MATERIAL AND METHODS: Patients tricuspid aortic valves undergoing elective open-

heart surgery for ascending aortic- and/or aortic valve replacement were included. Aortic

specimens from organ donors were obtained through the University of Miami Tissue Bank,

USA. Protein expression/localization and differences in aortic intima-media gene expression

were assessed using immunohistochemistry and transcriptomics, respectively. Ten-year aortic

growth was measured using echocardiography. In total 142 patients were included across

experiments (mRNA expression n=44, immunohistochemistry n=49, 10-year follow-up

n=49).

RESULTS: Aortic regurgitation was associated with the presence of oxidized apolipoprotein

B-containing lipoproteins and infiltrating CD68+ cells in the non-dilated ascending aortic

media, which was not observed in aortas of patients with aortic stenosis. Assessing factors

influencing lipoprotein retention showed increased levels of genes encoding core proteins of

proteoglycans (HSPG2, CSPG4, ACAN, and BGN) in patients with regurgitant valves,

compared with aortas from patients with stenotic valves. Moreover, dilated aortas of patients

with aortic regurgitation exhibited higher levels of the receptor for oxidized low-density

2

lipoprotein, OLR1, which correlated positively with inflammatory markers in both dilated and

non-dilated aortas. Surgical replacement of regurgitant aortic valves mitigated long-term

aortic growth, in contrast to replacement of stenotic valves, which was associated with

continuous aortic dilation.

CONCLUSIONS: The natural history of ascending aortic aneurysm in patients with

tricuspid aortic valves involves medial lipoprotein retention and oxidation with subsequent

OLR1-driven pathological inflammation, and can be mitigated by replacement of the

3

regurgitant aortic valve.

Introduction

Degenerative ascending aortic aneurysm is a silent, potentially fatal disease¹. It manifests as a progressive enlargement of the aortic lumen due to destructive changes in the aortic connective tissue. Pathologically it is characterized by vascular smooth muscle cell loss, extracellular matrix remodeling and low-grade inflammation²⁻⁴. The mechanism underlying its onset remains elusive, and no medical therapy or prognostic factor has yet been identified. Interestingly, non-canonical atherosclerotic processes have recently been described in the aneurysmal intima/media of patients with tricuspid aortic valves, signified by a pathological accumulation of macrophages and a disturbed lipid metabolism⁵. In our recent work, we could further enhance these findings by the identification infiltrating CD68+ immune cells expressing Secreted Phosphoprotein 1 that correlated with aortic dimensions and an augmented expression of inflammatory markers⁶. The mechanism enabling immune cells to migrate into to the sub-intimal space to facilitate inflammation initiation remains, however, unknown.

Notably, patients with tricuspid aortic valves undergoing surgery for ascending aortic aneurysm often present with concomitant aortic valve regurgitation^{7,8}. Equivalent patients with aortic stenosis, on the other hand, seem to be protected against proximal aneurysm development⁹. Regurgitation involves an inadequate closure of the aortic valve, causing backflow and flow-reversals in the proximal aorta¹⁰ with less laminar flow and decreased anti-inflammatory endothelial signaling¹¹. This obviously alters endothelial cell function and facilitates infiltration of e.g., lipoprotein and leukocytes into the aortic wall¹². Moreover, mild medial degeneration and smooth muscle cell phenotypic alterations¹³ has previously been reported in patients with aortic regurgitation without ascending aortic dilatation^{14–16}, and aortic regurgitation per se has been associated with more adverse outcomes following

ascending aortic surgery^{8,17}. In the present study, we sought to investigate the natural history of ascending aortic aneurysm formation in patients with tricuspid aortic valves, hypothesizing that regurgitant blood flow in the proximal aorta is associated with lipoprotein infiltration and retention, and consequently, activation of inflammation and medial remodeling.

Material and Methods

Patients

The present study includes patients from the Advanced Study of Aortic Pathology (ASAP) and Disease of the Aortic Valve, Ascending Aorta and Coronary Artery (DAVAACA) cohorts 18,19. In short, all patients underwent elective open-heart surgery for aortic valve disease and/or ascending aortic aneurysm at the Karolinska University Hospital, Stockholm, Sweden. Tissue biopsies were collected from the anterior part of the dilated ascending aorta, or at the site of aortotomy a few centimeters above the aortic valve from patients undergoing isolated aortic valve replacement. Biopsies of the internal thoracic artery were collected from patients included in the ASAP cohort. Ascending aortas with diameters > 45 mm were classified as dilated. Ascending aortic diameters were determined by perioperative transesophageal echocardiography. Patients with syndromic aortic pathologies or ascending aortic dissection were excluded. Analogous control tissues were acquired from organ donors with no documented history of valvular heart disease, through collaboration with Nova Southeastern University and the University of Miami Tissue Bank. A description of the control cohort can be found elsewhere²⁰. Ethical approval for the use of all tissues included in the study were obtained from the regional ethics review committee in Stockholm. Nonoverlapping patients were selected for mRNA expression (n=44) and immunohistochemistry

10-year follow up

Patients included in the ASAP cohort were re-called 10 years after surgery and aortic diameters were measured using echocardiography in those accepting to participate in the follow-up. Of the initial 600 ASAP patients, 419 were alive at the time of the follow-up, of

6

analysis, respectively (in total n=49), supplementary table S1.

which 81.6% (n= 342) accepted to participate. Of these, 210 patients had undergone isolated

valve replacement, 80 of which had a tricuspid aortic valve (remaining 130 patients had a

bicuspid aortic valve and were not included). After exclusion of patients who have had an

event in their ascending agrta prior to follow-up (n=4), or patients with incomplete

echocardiographic measurements (n=9 at follow-up, n=18 pre-operatively)), a total of 49

patients remained (n=12 regurgitation and n=37 with stenosis) in the final analysis. Mean

follow-up time from surgery to echocardiography was 10.3 years.

mRNA extraction and gene expression analysis

The intima-media layer was separated from the aortic tissue through adventectomy and

mRNA was extracted from the intima-media portion using the RNeasy kit (Qiagen). Global

gene expression was measured using the Affymetrix GeneChip® Human Exon 1.0 ST array

and protocols, as previously described²¹, in 23 patients with non-dilated aortas (n=11 with

7

stenosis, and n=12 with regurgitation) and 21 patients with dilated aortas (n=20 with

complete aortic diameters).

Immunohistochemistry

Cryosections (8 µm) of aortic surgical biopsies were fixed in acetone and blocked with 10%

goat serum with 0.1% Tween for 30 min. Sections were then incubated overnight at 4°C with

primary antibodies: anti-apoB (1:1000), CD68 (1:100), OxLDL (1:500), and OLR1 (1:500).

For ApoB, slides were incubated with biotinylated goat anti-mouse secondary antibody,

followed by streptavidin 568-conjugated fluorophore. Autofluorescence was quenched with

0.01% Sudan black. OxLDL and LOX-1 were visualized with a 647 fluorophore-conjugated

secondary anti-rabbit antibody, and CD68 with a 568 fluorophore-conjugated anti-mouse

antibody. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and

sections mounted in Fluoromount-G. Stainings were visualized using a laser scanning

confocal microscope. Acetone-fixed cryosections were also stained with Oil-red O,

counterstained with Hematoxylin-Q, and examined with a brightfield scanner.

A portion of the biopsies were fixed in 4% paraformaldehyde, embedded in paraffin,

and sectioned at 5 µm. Immunostaining for CD68 was performed overnight at 4°C on

deparaffinized sections after antigen retrieval, endogenous peroxidase quenching, and

blocking with 20% goat serum. Biotinylated goat anti-mouse IgG was used as the secondary

antibody (1:1,500) with avidin-biotin peroxidase complex added for visualization with DAB.

Sections were counterstained with hematoxylin, rehydrated and mounted. Hematoxylin-eosin

staining was performed following manufacturer instructions. Sections were examined using a

brightfield scanner.

Image analysis

Quantifications of signal intensity was performed in Fiji (Version 2.9.0, ImageJ2) upon

sectioning subintimal and medial region for ApoB, oxLDL and LOX-1. CD68+ positive cell-

ratio quantification was performed in Qupath (version 0.5.0, QuPath) averaging the ratio of

positive cells to all cells in three randomly selected intima-media regions.

Hematoxylin-eosin was used to assess overall medial degeneration. Parameter

definitions given by the consensus statement on noninflammatory aortic disease were

adapted²². Briefly, the severity of medial disorganization was assessed by consecutive

number of disrupted lamellar units in digital images. Severity was rated on a scale of 0 to 3,

where 0 equals no apparent pathology, 1 equals 2-4 consecutive lamellar units affected, 2

8

corresponds to 5-9 and 3 represents >10.

Statistical analysis

Baseline characteristics are presented as means (standard deviation) for continuous variables,

and ratio (percentage) for categorical variables, with differences analyzed using Mann-Whitney U test and Fisher's exact test for continuous and categorical variables, respectively. Differences in fluorescence intensity were compared using the Kruskal-Wallis test followed by Dunn's multiple comparisons test, or using Brown-Forsythe and Welch ANOVA with Dunnett's T3 multiple comparisons test. The Mann-Whitney U test was employed when appropriate. 10-year aortic growth was evaluated using Wilcoxon matched pairs signed rank test. Differential gene expression was analyzed using student's t-test, assuming unequal

(v1.4). The Reactome canonical pathway was utilized to minimize redundancy. Correlations

variance. Functional enrichment was determined using the msigdbr package in Rstudio

were assessed using Pearson's correlation. A p-value <.05 was considered for statistical

significance unless otherwise stated. Statistical analysis was carried out using GraphPad

Prism 10 (v10.1.1) or Rstudio (v1.4).

Results

Aortic regurgitation is associated with infiltration of lipoproteins and immune cells in the non-dilated aortic wall

Immunohistochemical evaluation of aortic biopsies revealed striking differences in sub-intimal expression of apoB, Oil Red O+ lipids, oxLDL, and CD68+ macrophages (Fig. 1A) between patients with aortic regurgitation and those with aortic stenosis. Specifically, a gradually reduced staining intensity, 50-100 µm into the medial layer, of apoB lipoproteins, Oil Red O+ lipids, oxLDL, and CD68+ macrophages was exclusively seen in non-dilated aortas of patients with aortic regurgitation. The gradually reduced staining suggesting infiltration from the aortic lumen. We could not see any intimal or medial staining of any of the above-mentioned proteins in patients with aortic stenosis. To investigate whether the

9

observed lipoprotein retention was restricted to the ascending aorta, we also examined

biopsies obtained from the internal thoracic artery, showing no medial infiltration of apoB in

either patients with stenosis or regurgitation (Fig. 1B). Notably, although not statistically

significant, patients with stenotic valves showed a tendency towards higher plasma

cholesterol levels (P=.06) and were older (P=.021) that patients with aortic regurgitation.

Low-density lipoprotein cholesterol concentrations did not differ between groups (P=.74)

(Table 1). Aortic biopsies obtained from organ donors without any documented valvulopathy

showed sub-intimal staining of apoB but had no detectable levels of lipids or oxidized

lipoproteins, indicating a lack of LDL-particle retention.

Matrix remodeling may impact apoB lipoprotein retention in aortas of aortic regurgitation

patients

In line with previous publications 11-13, an increased medial degradation of the non-dilated

ascending aorta, including fragmented elastic lamellae, was seen in patients with aortic

regurgitation compared with patients with aortic stenosis (P=.039) (Fig. 2A). No medial

degeneration was seen in organ donors devoid of documented valve disease (Fig. 2A). Global

gene expression analysis revealed that genes associated with extracellular matrix (ECM)

organization and ECM proteoglycans were significantly up-regulated in non-dilated aortas of

patients with aortic regurgitation compared with aortic stenosis patients (Fig. 2B, top 100

differentially expressed genes are shown in supplementary table S2). Specifically, we

observed increased mRNA levels of key genes encoding core proteins of LDL-binding

proteoglycans²³ (HSPG2, CSPG4, ACAN, and BGN) (Fig 2C), suggesting a milieu favoring

10

lipoprotein retention.

Oxidized lipoprotein receptor 1 (OLR1) as a driver of degenerative ascending aortic

aneurysm formation

To further clarify the role of lipoprotein oxidization in aneurysm formation, we conducted a

functional enrichment analysis of differentially expressed genes between non-dilated and

dilated ascending aortas of patients with aortic regurgitation. This showed an up-regulation of

genes related to the innate immune system as key in the aneurysmal process. The most highly

up-regulated genes were CLEC5A, OLR1, TREM1, PTPRC, and CCR2 (Fig. 3A) (full list of

genes within this set in supplementary table S3). Interestingly, GeneMania analysis showed

that oxidized lipoprotein receptor 1 (OLR1) physically interacts with apoB (Fig. 3B). OLR1

was highly expressed in dilated specimens and co-localized with CD68+ cells (Fig. 3C).

Moreover, OLR1 mRNA levels correlated positively with mRNA levels of inflammatory

markers, in both dilated and non-dilated aortas (Fig. 3D). In addition, OLR1 mRNA levels

correlated positively with ascending aortic diameter (Fig. 3E).

Surgical aortic valve replacement for aortic regurgitation, but not aortic valve stenosis

mitigates ascending aortic growth

As part of a follow-up study, in which ASAP-patients were re-called 10 years after ascending

aortic and/or aortic valve surgery for evaluation of long-term aortic growth, we evaluated

ascending aortic growth in relation to valve disease in patients undergoing isolated aortic

valve replacement. Interestingly, aortic valve replacement for aortic regurgitation, but not

aortic stenosis, mitigated further ascending aortic expansion (Fig. 4), with a mean growth of

11

0.86 mm vs. 1.67 mm for a rtic regurgitation and a ortic stenosis, respectively.

Discussion

Ascending aortic aneurysm is a silent, potentially fatal disease with no proven medical therapy. This is primarily due to a limited understanding of underlying pathological mechanisms and factors triggering the onset of disease. Here we show that the natural history of ascending aortic aneurysm formation in patients with tricuspid aortic valves involves subintimal infiltration of ApoB-carrying lipoproteins, which are retained and oxidized in the aortic wall. Up-regulation of oxidized low-density lipoprotein receptor 1 by infiltrating CD68+ cells further trigger an inflammatory cascade, most likely contributing to medial fibrosis and aneurysm formation. Importantly, the observed phenotype was only seen in patients with isolated aortic valve regurgitation, and not in patients with aortic stenosis who are mostly protected from aneurysm development. Surgical replacement of a regurgitant aortic valve mitigated further aortic expansion, whilst replacement of a stenotic valve was associated with a significant long-term aortic growth. Collectively this highlights oxLDL as a key player in the initiation of ascending aortic aneurysm formation and provides important insights towards improved disease prevention and management.

It has long been recognized that aortic regurgitation carries prognostic significance in conditions affecting the ascending aorta²⁴, and histopathological studies have shown that aortic regurgitation is associated with medial degenerative insults already prior to aortic dilatation¹⁴. Here we further show that also genes encoding core proteins of LDL-binding proteoglycans²³ are highly up-regulated in non-dilated aortas of patients with regurgitant valves, creating a favorable milieu for retention of infiltrating lipoproteins and thus, lipoprotein oxidation. Additionally, experimentally induced flow reversals, like those caused by a regurgitant aortic valve, has been reported to influence endothelial lipid biology²⁵ and may contribute to the disease process.

12

The fact that expression of the atherogenic scavenger receptor Oxidized Low Density Lipoprotein Receptor 1 (*OLR1*) positively correlated with aortic diameter, and was significantly up-regulated in the aneurysmal aorta, also suggests a role of oxLDL in the progression of aneurysm formation. Indeed, *OLR1* mRNA levels correlated with the expression of inflammatory markers, in both dilated and non-dilated aortas, and its expression was co-localized with infiltrating CD68+ cells. Interestingly, innate immune cells are prone to greater inflammatory activation by oxLDL²⁶, which in the context of AscAA, may exacerbate downstream immune cell-associated degeneration⁶. Furthermore, a subcluster of OLR1+ macrophages were recently demonstrated in dissecting aortic tissue, that promoted formation of neutrophil extracellular traps²⁷. This indeed suggests a role for *OLR1* in the pathogenesis of ascending aortic aneurysm formation and warrants investigation as to whether OLR1 can be targeted pharmacologically as a preventive measure or diagnostic marker. Meanwhile, aortic valve replacement remains an effective, although invasive, therapy for patients with tricuspid aortic valves and aortic valve regurgitation, as indicated by the attenuation of long-term aortic growth following surgical valve replacement.

The present study also contests the controversial hypothesis of post-stenotic aortic dilatation²⁸, where aortic stenosis *per se* is suggested to exacerbate ascending aortic growth. We could not see any infiltration of ApoB-containing lipoproteins, nor many CD68+ cells, into the subintima of patients with aortic stenosis, despite the fact that total cholesterol levels were higher in these patients compared with patients with regurgitant valves. It can be speculated that this may be due to high-velocity flow-jets imposed on the aortic wall as a result of aortic stenosis, limiting the exposure time of circulating lipoproteins to the endothelium and the transcytosis machinery^{29,30}, and thus, hamper infiltration. However, interestingly, surgical replacement of a stenotic valve resulted in a significant ascending aortic growth over a period of 10 years. Although some aortic growth can occur without

valvular abnormalities and with increasing age³¹, it is tempting to speculate that this may be a

result of an adapted vascular smooth muscle cell phenotypic switch to compensate for the

increased wall stress caused by the stenotic valve¹³, making the ascending aorta less resilient

to pulsatile flow^{32,33}. Indeed, an increased aortic stiffness has been observed in patients with

aortic stenosis compared with patients with regurgitant valves following aortic valve

replacement³⁴.

Limitations

The present report highlights novel results on the pathogenesis of degenerative AscAA but

bases itself in a surgical cohort and therefore, limits the result to patients meeting the criteria

for surgical intervention. Furthermore, longitudinal investigations do not consider changes

in medical management of patients, and causality can be proven from the present study.

Conclusion

Collectively, results from the present study suggest that oxidative modifications of

lipoproteins and OLR1-expressing macrophages contribute to the early pathogenesis of

ascending aortic aneurysm by propagating inflammation and matrix degeneration, ultimately

leading to aortic dilatation. The causal relationships between regurgitant flow, lipid

retention, and aortic dilatation, however, need to be confirmed.

Ethics approval and consent to participate

The study was approved by the Human Research Ethics Committee in Stockholm

(2006/784-31/1 and 2012/1633-31/4). Written informed consent was obtained from all

patients following the declaration of Helsinki. The collection and scientific use of aortic

14

tissues from organ donors was approved by the Human Research Ethics Committee in

Stockholm (2017/2268-31).

Funding

This work was supported by the Swedish Research Council [2020-01442]; the Swedish

Heart-Lung Foundation [20210521, 20220136]; Stockholm County Council [FoUI-985101];

the Magnus Bergvall Foundation; the Schörling Foundation, and a donation by Mr. Fredrik

Lundberg. The funding bodies had no role in the study's design, data collection, analysis,

interpretation, or manuscript writing.

Acknowledgements

Not applicable.

Competing interests

Nothing to declare.

Data availability

The datasets used and/or analyzed in the current study are available from the corresponding

15

author upon request.

References

- 1. Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms. *Journal of Vascular Surgery*. 2012;56(2):565–571.
- 2. Erdheim J. Medionecrosis aortae idiopathica cystica. *Virchows Archiv für Pathologische Anatomie und Physiologie und für Klinische Medizin*. 1930;276(1):187–229.
- 3. Halushka MK, Angelini A, Bartoloni G, Basso C, Batoroeva L, Bruneval P, Buja LM, Butany J, D'Amati G, Fallon JT, Gallagher PJ, Gittenberger-De Groot AC, Gouveia RH, Kholova I, Kelly KL, et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: II. Noninflammatory degenerative diseases Nomenclature and diagnostic criteria. *Cardiovascular Pathology*. 2016;25(3):247–257.
- 4. Freiholtz D, Bergman O, Lång K, Poujade FA, Paloschi V, Granath C, Lindeman JHN, Olsson C, Franco-Cereceda A, Eriksson P, Björck HM. Bicuspid aortic valve aortopathy is characterized by embryonic epithelial to mesenchymal transition and endothelial instability. *Journal of Molecular Medicine*. 2023;1:1–11.
- 5. Doppler C, Messner B, Mimler T, Schachner B, Rezk M, Ganhör C, Wechselberger C, Müller M, Puh S, Pröll J, Arbeithuber B, Müller T, Zierer A, Bernhard D. Noncanonical atherosclerosis as the driving force in tricuspid aortic valve associated aneurysms A trace collection. *Journal of Lipid Research*. 2023;64(3):100338.
- 6. Freiholtz D, Bergman O, Pradhananga S, Lång K, Poujade FA, Granath C, Olsson C, Franco-Cereceda A, Sahlén P, Eriksson P, Björck HM. SPP1/osteopontin: a driver of fibrosis and inflammation in degenerative ascending aortic aneurysm? *Journal of Molecular Medicine*. 2023;101(10):1323–1333.
- 7. Roberts WC, Vowels TJ, Ko JM, Filardo G, Hebeler RF, Henry AC, Matter GJ, Hamman BL. Comparison of the structure of the aortic valve and ascending aorta in adults having aortic valve replacement for aortic stenosis versus for pure aortic regurgitation and resection of the ascending aorta for aneurysm. *Circulation*. 2011;123(8).
- 8. Wang Y, Wu B, Li J, Dong L, Wang C, Shu X. Impact of Aortic Insufficiency on Ascending Aortic Dilatation and Adverse Aortic Events after Isolated Aortic Valve Replacement in Patients with a Bicuspid Aortic Valve. *Annals of Thoracic Surgery*. 2016;101(5):1707–1714.

- 9. Jackson V, Olsson C, Eriksson P, Franco-Cereceda A. Aortic dimensions in patients with bicuspid and tricuspid aortic valves. *Journal of Thoracic and Cardiovascular Surgery*. 2013;146(3):605–610.
- 10. Stein PD, Sabbah HN. Turbulent blood flow in the ascending aorta of humans with normal and diseased aortic valves. *Circulation Research*. 1976;39(1).
- 11. Suo J, Ferrara DE, Sorescu D, Guldberg RE, Taylor WR, Giddens DP. Hemodynamic shear stresses in mouse aortas: Implications for atherogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2007;27(2):346–351.
- 12. Andueza A, Kumar S, Kim J, Kang DW, Mumme HL, Perez JI, Villa-Roel N, Jo H. Endothelial Reprogramming by Disturbed Flow Revealed by Single-Cell RNA and Chromatin Accessibility Study. *Cell Reports*. 2020;33(11):108491.
- 13. Balint B, Bernstorff IGL, Schwab T, Schäfers H-J. Aortic regurgitation provokes phenotypic modulation of smooth muscle cells in the normal ascending aorta. *The Journal of thoracic and cardiovascular surgery*. 2023.
- 14. Balint B, Federspiel JM, Schwab T, Ehrlich T, Ramsthaler F, Schäfers HJ. Aortic Regurgitation Is Associated With Ascending Aortic Remodeling in the Nondilated Aorta. *Arteriosclerosis, thrombosis, and vascular biology.* 2021;41(3):1179–1190.
- 15. Sequeira Gross TM, Lindner D, Ojeda FM, Neumann J, Grewal N, Kuntze T, Blankenberg S, Reichenspurner H, Westermann D, Girdauskas E. Comparison of microstructural alterations in the proximal aorta between aortic stenosis and regurgitation. *Journal of Thoracic and Cardiovascular Surgery*. 2021;162(6):1684–1695.
- 16. Benedik J, Pilarzcyk K, Wendt D, Price V, Tsagakis K, Perrey M, Baba HA, Jakob H. Is there any difference in aortic wall quality between patients with aortic stenosis and those with regurgitation? *European Journal of Cardio-thoracic Surgery*. 2013;44(4).
- 17. Chumachenko P V., Postnov AY, Ivanova AG, Afanasieva OI, Afanasiev MA, Ekta MB, Sukhorukov VN, Kheimets GI, Sobenin IA. Thoracic aortic aneurysm and factors affecting aortic dissection. *Journal of Personalized Medicine*. 2020;10(4):1–8.
- 18. Jackson V, Petrini J, Caidahl K, Eriksson MJ, Liska J, Eriksson P, Franco-Cereceda A. Bicuspid aortic valve leaflet morphology in relation to aortic root morphology: A study of 300 patients undergoing open-heart surgery. *European Journal of Cardio-thoracic Surgery*. 2011;40(3).
- 19. Granath C, Freiholtz D, Bredin F, Olsson C, Franco-Cereceda A, Björck HM. Acetylsalicylic Acid Is Associated With a Lower Prevalence of Ascending Aortic Aneurysm

- and a Decreased Aortic Expression of Cyclooxygenase 2. *Journal of the American Heart Association*. 2022;11(9).
- 20. Granath C, Noren H, Björck H, Simon N, Olesen K, Rodin S, Grinnemo KH, Österholm C. Characterization of Laminins in Healthy Human Aortic Valves and a Modified Decellularized Rat Scaffold. *BioResearch Open Access*. 2020;9(1):269.
- 21. Folkersen L, Wågsäter D, Paloschi V, Jackson V, Petrini J, Kurtovic S, Maleki S, Eriksson MJ, Caidahl K, Hamsten A, Michel JB, Liska J, Gabrielsen A, Franco-Cereceda A, Eriksson P. Unraveling divergent gene expression profiles in bicuspid and tricuspid aortic valve patients with thoracic aortic dilatation: The ASAP study. *Molecular Medicine*. 2011;17(11).
- 22. Halushka MK, Angelini A, Bartoloni G, Basso C, Batoroeva L, Bruneval P, Maximilian Buja L, Butany J, Fallon JT, Gallagher PJ, Gittenberger-de Groot AC, Gouveia RH, Kholova I, Kelly KL, Leone O, et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association For European Cardio-vascular Pathology: II. Noninflammatory degenerative diseases-nomenclature and diagnostic criteria Cardiovascular Pathology. 2016.
- 23. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. *Atherosclerosis*. 1998;139(2):205–222.
- 24. Wang Y, Wu B, Li J, Dong L, Wang C, Shu X. Impact of Aortic Insufficiency on Ascending Aortic Dilatation and Adverse Aortic Events After Isolated Aortic Valve Replacement in Patients With a Bicuspid Aortic Valve. *The Annals of thoracic surgery*. 2016;101(5):1707–1714.
- 25. Hong S-G, Kennelly JP, Williams KJ, Bensinger SJ, Mack JJ, Young CE. PREPRINT: Flow-Mediated Modulation of the Endothelial Cell Lipidome. *bioRxiv*. 2024:2024.06.13.598934.
- 26. Groh LA, Ferreira A V., Helder L, Heijden CDCC van der, Novakovic B, Westerlo E van de, Matzaraki V, Moorlag SJCFM, Bree LC de, Koeken VACM, Mourits VP, Keating ST, Puffelen JH van, Hoischen A, Joosten LAB, et al. oxLDL-Induced Trained Immunity Is Dependent on Mitochondrial Metabolic Reprogramming. *Immunometabolism*. 2021;3(3).
- 27. Wang L, Zhao Y, Mo F, Li Z, Yuan Y, Hong S, Wang E, Yuzchong Z, Fu W. PREPRINT: Integrated Multi-Omics Profiling Reveals Neutrophil Extracellular Traps Promote Aortic Dissection. 2023.

- 28. Wilton E, Jahangiri M. Post-stenotic aortic dilatation. Journal of cardiothoracic surgery. 2006;1(1).
- 29. Libby P. The changing landscape of atherosclerosis. *Nature*. 2021;592.
- 30. Armstrong SM, Sugiyama MG, Fung KYY, Gao Y, Wang C, Levy AS, Azizi P, Roufaiel M, Zhu SN, Neculai D, Yin C, Bolz SS, Seidah NG, Cybulsky MI, Heit B, et al. A novel assay uncovers an unexpected role for SR-BI in LDL transcytosis. Cardiovascular Research. 2015;108(2):268-277.
- Mancusi C, Manzi MV, Lembo M, Fucile I, Basile C, Bardi L, Morisco C, De Luca 31. N, Bossone E, Trimarco B, Izzo R, De Simone G, Esposito G. Normalization of ascending aorta dimension for body size influences pathophysiologic correlation in hypertensive patients: the Campania Salute Network. European Journal of Preventive Cardiology. 2023;30(16):1774–1780.
- 32. Plunde O, Franco-Cereceda A, Bäck M. Cardiovascular Risk Factors and Hemodynamic Measures as Determinants of Increased Arterial Stiffness Following Surgical Aortic Valve Replacement. Frontiers in Cardiovascular Medicine. 2021;8:754371.
- 33. Hannuksela M, Johansson B, Carlberg B. Aortic stiffness in families with inherited non-syndromic thoracic aortic disease. Scandinavian Cardiovascular Journal. 2018;52(6).
- 34. Plunde O, Bäck M. Arterial Stiffness in Aortic Stenosis and the Impact of Aortic Valve Replacement. Vascular Health and Risk Management. 2022;18:117.

Tables

Table 1. Patient characteristics of individuals examined for ApoB-infiltration (immunohistochemistry).

	Aortic Stenosis	Aortic Regurgitation	P-value
N	11	12	-
Age, years	65.08 (14.9)	57.9 (11.3)	.021
Male sex	8 (73)	8 (67)	1.0
BSA, m ²	1.98 (0.2)	1.94 (0.2)	.52
Cholesterol,			
mmol/L	4.91 (1.3)	4.16 (1.1)	.060
LDL-			
cholesterol,			
mmol/L	3.02 (1.2)	2.3 (1)	.74
hsCRP, mg/L	2.4 (2.8)	6.4 (16.2)	.37
Diabetes	0 (0)	0 (0)	1.0
Hypertension	6 (55)	8 (67)	.68
Chronic			
inflammation	0 (0)	0 (0)	1.0
Vascular			
disease	4 (36)	1 (8)	.16
Current			
smoker	6 (55)	4 (33)	.41

Continuous variables are presented as mean (SD); ordinal variables are presented as n (ratio). Mann-Whitney and Fisher's exact test for numerical and categorical variables respectively. Body surface area, BSA; high-sensitivity C-reactive protein, hsCRP; low-density lipoprotein, LDL.

Figure captions




Figure 1. Infiltration of lipoproteins and inflammatory cells in the ascending aorta.

Immunofluorescent staining of apolipoprotein(apo)B, oxidized(ox)LDL, **(A)** immunohistological staining of CD68 in ascending aortic biopsies, and representative micrographs of Oil red O (ORO) staining. Kruskal-Wallis test with Dunn's multiple comparisons test for apoB and Brown-Forsythe and Welch ANOVA with Dunnet's T3 multiple comparisons test for oxLDL and CD68. (B) ApoB staining in internal thoracic arteries with quantification of staining intensity in media. Mann-Whitney test (p-value=.48). Scale micrographs. 100 DAPI=4',6-diamidino-2-phenylindole, bar all μm in HTX=hematoxylin.




Figure 2. Matrix remodeling in the non-dilated ascending aorta associates with aortic regurgitation

(A) Hematoxylin-eosin (HTX) staining of ascending aortic biopsies. Mann-Whitney test. Scale bar 250 µm in all micrographs. (B) Pathway analysis of differentially expressed genes between patients with aortic regurgitation vs. aortic stenosis, non-dilated aortas. (C) Proteoglycan mRNA levels in non-dilated aortic biopsies from patients with aortic regurgitation vs. stenosis. Unpaired t-test with Welch's correction for mRNA level comparisons. ECM=extracellular matrix.




Figure 3. Immune cell OLR1 expression drives aneurysm progression through oxLDL-interactions

(A) Pathway analysis of differentially expressed genes, dilated vs. non-dilated aortas of patients with aortic regurgitation. (B) Volcano plot of differentially expressed genes within the innate immune system term. (C) GeneMania physical interaction plot of top five differentially expressed genes. (D) Immunofluorescent double staining of CD68 and OLR1 in biopsies from dilated and non-dilated aortas of patients with aortic regurgitation, Mann-Whitney test. (E) Gene correlation matrix of Pearson R values, patients with aortic regurgitation. The upper right part of the matrix represents non-dilated aortas, and the lower left part representdilated aortas. (F) Linear regression analysis of ascending aortic diameter measured by perioperative echocardiography and OLR1 mRNA levels in patients with aortic

regurgitation. Scale bar 100 µm in all micrographs. DAPI=4',6-diamidino-2-phenylindole, LOX-1=Lectin-like oxidized lipoprotein receptor 1.




Figure 4. Surgical aortic valve replacement attenuates aortic growth in aortic regurgitation, not aortic stenosis

Transthoracic aortic echocardiography follow-up data for ascending aorta diameter 10 years after aortic valve surgery and biopsy collection, Wilcoxon matched pair test.